IMPLEMENTATION OF THE DENGUE “SCREEN AND VACCINATE” STRATEGY
A toolkit for country decision makers, program planners and local implementers Based on results of long-term clinical trial data confirming differences in dengue vaccine performance based on prior dengue infection, Sanofi Pasteur proposed an update label for...
EXPERT MEETING FOR DENGUE VACCINE IMPLEMENTATION IN LATIN AMERICA
For a better understanding of the new recommendations for the dengue vaccine implementation. The 6th Expert meeting on dengue vaccine implementation in Latin America was held June 22 and 23 2018 in Lima, Peru. The meeting convened a permanent group of Latin America...
TECHNICAL SUPPORT TO DENGUE VACCINE IMPLEMENTATION: INFORMATION FOR DECISION-MAKING
Since December 2015, dengue is a vaccine-preventable disease. What are the key factors to consider for vaccine introduction. The CYD-TDV vaccine (commercial name Dengvaxia®) is a dengue tetravalent vaccine (live attenuated), that has been licensed for the prevention...